Nulojix FDA Approval History
FDA Approved: Yes (First approved June 15, 2011)
Brand name: Nulojix
Generic name: belatacept
Dosage form: Injection
Company: Bristol-Myers Squibb Company
Treatment for: Organ Transplant, Rejection Prophylaxis
Nulojix (belatacept) is a selective T-cell costimulation blocker indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant.
Development timeline for Nulojix
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.